A phase III TRANSFORM-2 trial is also ongoing, evaluating the combination of Navitoclax and ruxolitinib vs the best available therapy (BAT) in adults with relapsed or refractory myelofibrosis resistant to single-agent JAK2 inhibition. The gene discussed is JAK2; the disease is myelofibrosis.